Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Heart

• Publication date

  2007-10-04

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1136/hrt.2007.127217PMID 17916665
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Unit Costs of Health and Social Care 2016

  2015cited by this paper
• Hypertension: Management of hypertension in adults in primary care: partial updateNational Institute for Health and Clinical Excellence ([British] National Collaborating Centre for Chronic Conditions, England; British Hypertension Society, England; Newcastle Guideline Development and Research Unit,

  2007cited by this paper
• 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

  2007cited by this paper
• An Introduction to the Bootstrap

  2007cited by this paper
• Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy

  2007cited by this paper
• Statin therapy of calcific aortic stenosis: hype or hope?

  2006cited by this paper
• PCI reduces utility loss after myocardial infarction in Sweden.

  2006cited by this paper
• Markov Models in Medical Decision Making : A Practical Guide

  2006cited by this paper
• Prevention of Cardiovascular Events With an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required Versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Tri

  2006cited by this paper
• Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

  2005cited by this paper
• Cost-Effectiveness of Atorvastatin for the Prevention of Coronary and Stroke Events: An Economic Analysis of the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA)

  2005cited by this paper
• Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri

  2005cited by this paper
• 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension

  2004cited by this paper
• Swedish population health-related quality of life results using the EQ-5D

  2004cited by this paper
• European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension

  2003cited by this paper
• 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension

  2003cited by this paper
• Unit costs of Health and Social Care 2002

  2003cited by this paper
• 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.

  2003cited by this paper
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

  2003cited by this paper
• Definition, interpretation and calculation of cost-effectiveness acceptability curves.

  2000cited by this paper
• Direct medical costs for patients with type 2 diabetes in Sweden

  2000cited by this paper
• Variations in population health status: results from a United Kingdom national questionnaire survey

  1998cited by this paper
• Incorporating Future Costs in Medical Cost-Effectiveness Analysis

  1997cited by this paper
• Accounting for Future Costs in Medical Cost-Effectiveness Analysis

  1997cited by this paper
• Accounting for future costs in medical cost-effectiveness analysis.

  1997cited by this paper
• Markov Models in Medical Decision Making

  1993cited by this paper
• Cost-effectiveness of the treatment of hypertension.

  1993cited by this paper
• Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

  1990cited by this paper

• Cost-effectiveness Analyses of Antihypertensive Medicines: A Systematic Review

  2017cites this paper
• Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice

  2017cites this paper
• University of Birmingham Cost effectiveness of support for people starting a new medication for a long-term condition through community pharmacies

  2017cites this paper
• Cost-effectiveness Study of Antihypertensive Drugs in Mumbai, India

  2016cites this paper
• Economic evaluation of factorial randomised controlled trials

  2015cites this paper
• A short-term cost-effectiveness analysis of hypertension treatment in Greece.

  2014cites this paper
• The Anglo-Scandinavian Cardiac Outcomes Trial: Implications and Further Outcomes

  2012cites this paper
• A cost-utility analysis of hypertension treatment in Greece: assessing the impact of age, sex and smoking status, on outcomes

  2012cites this paper
• The Lifetime Cost Effectiveness of Amlodipine-Based Therapy Plus Atorvastatin Compared with Atenolol Plus Atorvastatin, Amlodipine-Based Therapy Alone and Atenolol-Based Therapy Alone

  2012cites this paper
• Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association.

  2011cites this paper
• [Optimization of the control of blood pressure. What contribution can be obtained from use of combinations of fixed doses of ace inhibitors and calcium channel blockers?].

  2011cites this paper
• Antihypertensive prescribing preferences in three South Indian Hospitals: cost analysis, physicians perspectives and emerging trends.

  2011cites this paper
• Women2011 Update: A Guideline From the American Heart Association Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in

  2011cites this paper
• 1. ACCF/AHA. (2007). Clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain. Circulation, 115, 402-

  2011cites this paper
• Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association.

  2011cites this paper
• Economic evaluation of home blood pressure monitoring with or without telephonic behavioral self-management in patients with hypertension.

  2010cites this paper
• The economic consequences of non‐adherence to lipid‐lowering therapy: results from the Anglo‐Scandinavian‐Cardiac Outcomes Trial

  2010cites this paper
• Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.

  2009cites this paper
• Amlodipine: a pharmacoeconomic review

  2009cites this paper
• Proteinuria and clinical outcomes in hypertensive patients.

  2009cites this paper
• Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine.

  2008cites this paper
• Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine

  2008cites this paper
• Selecting a fixed combination to improve morbidity/mortality: the weight of evidence with ASCOT

  2008cites this paper
• Aha Guideline Effectiveness-based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 Update a Guideline from the American Heart Association Executive Writing Committee Expert Panel Members Cvd Risk Assessment Table 1. Class Iii Interventions (not Useful/effective and May Be Harmfu

  year unknowncites this paper